Real-world Clinical Setting of Azacitidine Treatment in Patients with Intermediate‑2 or High Risk Myelodysplastic Syndromes
Latest Information Update: 27 May 2017
At a glance
- Drugs Azacitidine (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- Acronyms RETRO-AZA-MDS-001
- 27 May 2017 New trial record